Overview
VSTM market data
Price History
VSTM price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$3.02 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.34 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $3.43 – $11.25 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $529 · P/B 10.17 · P/S 10.67.
Company News
Verastem Oncology Doses First Participant In Its TARGET-D 203 Phase 2 Study Of VS-7375 To Treat Metastatic Colorectal CancerBenzinga · Jul 28, 2026, 8:02 PM
12 Health Care Stocks Moving In Thursday's After-Market SessionBenzinga · Jul 23, 2026, 9:10 PM
Verastem Oncology Doses First Patient In Phase 2 Trial Of VS-7375 For KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer And Untreated Asymptomatic Untreated Brain MetastasesBenzinga · Jul 22, 2026, 8:02 PM
These 7 Small Caps Are on Fire as the Second Half Begins: Here’s WhyBenzinga · Jul 21, 2026, 7:52 PM
RBC Capital Maintains Outperform on Verastem, Lowers Price Target to $14Benzinga · Jul 7, 2026, 4:25 PM
Verastem Oncology Data From TARGET-D 101 Phase 1/2 Clinical Study Of VS-7375 Shows Encouraging Clinical Activity Including Favorable Safety Profile; Broad Anti-Tumor Activity ObservedBenzinga · Jun 23, 2026, 8:10 PM
8-K filing — Verastem, Inc. (VSTM)SEC EDGAR · Jun 23, 2026, 8:02 PM
Verastem Stock Jumps As Data Shows Strong Survival Trends In Pancreatic CancerBenzinga · Jun 17, 2026, 4:50 PM
Verastem Announces Updated Safety, Efficacy Results From RAMP 205 Evaluating Avutometinib Plus Defactinib In Combination With Gemcitabine And Nab-Paclitaxel In First-Line Metastatic Pancreatic CancerBenzinga · Jun 17, 2026, 11:40 AM
Verastem Oncology Doses First Participant In Its TARGET-D-201 Phase 2 Registration-Directed Study Of VS-7375 To KRAS G12D-Mutated Metastatic Pancreatic Ductal CarcinomaBenzinga · Jun 16, 2026, 8:05 PM